BARCLAYS PLC - SAREPTA THERAPEUTICS INC ownership

SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 405 filers reported holding SAREPTA THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.53 and the average weighting 0.2%.

Quarter-by-quarter ownership
BARCLAYS PLC ownership history of SAREPTA THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$72,079
+42.6%
456,198
+16.8%
0.02%
+29.4%
Q1 2024$50,550
+18.4%
390,480
-11.8%
0.02%
+6.2%
Q4 2023$42,709
-31.9%
442,906
-14.4%
0.02%
-59.0%
Q3 2023$62,705
+37.4%
517,286
+29.8%
0.04%
+34.5%
Q2 2023$45,639
-27.0%
398,525
-12.1%
0.03%0.0%
Q1 2023$62,521
+16.3%
453,610
+9.3%
0.03%
+20.8%
Q4 2022$53,778
-99.8%
415,008
+49.0%
0.02%
-29.4%
Q3 2022$30,782,000
+95.6%
278,466
+32.6%
0.03%
+240.0%
Q2 2022$15,739,000
+284.0%
209,970
+300.2%
0.01%
+233.3%
Q1 2022$4,099,000
-63.3%
52,472
-57.7%
0.00%
+50.0%
Q4 2021$11,172,000
+98.1%
124,126
+103.6%
0.00%0.0%
Q3 2021$5,639,000
+294.1%
60,980
+231.5%
0.00%
+100.0%
Q2 2021$1,431,000
-64.4%
18,394
-65.9%
0.00%
-50.0%
Q1 2021$4,015,000
-71.1%
53,886
-33.9%
0.00%
-75.0%
Q4 2020$13,888,000
+9.9%
81,463
-9.5%
0.01%0.0%
Q3 2020$12,636,000
-30.9%
89,985
-21.1%
0.01%
-42.9%
Q2 2020$18,294,000
-51.3%
114,091
-70.3%
0.01%
-51.7%
Q1 2020$37,532,000
-40.9%
383,689
-22.1%
0.03%
-17.1%
Q4 2019$63,536,000
+160.8%
492,380
+52.2%
0.04%
+150.0%
Q3 2019$24,364,000
-66.1%
323,481
-31.6%
0.01%
-68.2%
Q2 2019$71,860,000
+83.7%
472,922
+44.1%
0.04%
+63.0%
Q1 2019$39,126,000
+86.1%
328,271
+70.4%
0.03%
+58.8%
Q4 2018$21,028,000
-31.1%
192,684
+1.9%
0.02%
-19.0%
Q3 2018$30,526,000
-50.2%
189,000
-59.2%
0.02%
-60.4%
Q2 2018$61,252,000
+308.2%
463,409
+128.8%
0.05%
+341.7%
Q1 2018$15,005,000
-50.9%
202,539
-63.1%
0.01%
-52.0%
Q4 2017$30,564,000
+6.5%
549,302
-13.2%
0.02%
-16.7%
Q3 2017$28,696,000
+303.9%
632,642
+200.2%
0.03%
+328.6%
Q2 2017$7,104,000
+25.2%
210,729
+10.0%
0.01%0.0%
Q1 2017$5,673,000
-78.1%
191,619
-79.7%
0.01%
-75.0%
Q4 2016$25,871,000
-77.3%
943,210
-49.3%
0.03%
-77.8%
Q3 2016$114,179,000
+476.8%
1,859,318
+79.1%
0.13%
+404.0%
Q2 2016$19,794,000
+11969.5%
1,038,010
+11901.5%
0.02%
Q1 2016$164,000
-98.7%
8,649
-97.3%
0.00%
-100.0%
Q4 2015$12,223,000
+19.3%
321,651
+0.4%
0.02%
+25.0%
Q3 2015$10,249,000
+288.7%
320,244
+264.5%
0.01%
+300.0%
Q2 2015$2,637,000
+9317.9%
87,869
+3977.4%
0.00%
Q1 2015$28,000
-90.4%
2,155
-89.6%
0.00%
Q4 2014$291,000
-37.3%
20,817
-5.8%
0.00%
Q3 2014$464,000
-30.4%
22,105
-3.9%
0.00%
-100.0%
Q2 2014$667,000
-67.3%
23,000
-73.0%
0.00%
-50.0%
Q1 2014$2,041,000
-85.0%
85,043
-87.5%
0.00%
-85.7%
Q4 2013$13,574,000
-72.6%
678,703
-35.5%
0.01%
-76.3%
Q3 2013$49,465,000
-52.9%
1,052,462
-61.8%
0.06%
-54.6%
Q2 2013$104,936,0002,758,6160.13%
Other shareholders
SAREPTA THERAPEUTICS INC shareholders Q4 2023
NameSharesValueWeighting ↓
Asymmetry Capital Management, L.P. 87,180$2,581,0003.60%
Perceptive Advisors 1,771,029$52,422,0002.99%
SPHERA FUNDS MANAGEMENT LTD. 483,047$14,298,0002.80%
HealthCor Management, L.P. 1,550,000$45,880,0002.10%
Camber Capital Management LP 1,350,000$39,960,0001.62%
Tourbillon Capital Partners, L.P. 1,537,518$45,511,0001.17%
Elk Creek Partners, LLC 562,522$16,651,0001.02%
EMERALD ADVISERS, LLC 818,705$24,234,0001.00%
EMERALD MUTUAL FUND ADVISERS TRUST 604,467$17,892,0000.82%
Carlson Capital, L.P. 1,845,702$54,633,0000.70%
View complete list of SAREPTA THERAPEUTICS INC shareholders